DUX4 and facioscapulohumeral muscular dystrophy: This approach could enable the identification of biomarkers to be exploited for the classification of FSHD patients, the staging of disease progression or the design of therapeutic approaches aimed at counteracting the disease (such as DUX4-targeting drugs).